Developer docs
API playgroundTry for free, no card

Search company profiles

EspeRare

Full company profile

uuid002trpq

Namestring
EspeRare
Websiteurl
esperare.org
Company typeenum
Private
Founded yearint
2013
Descriptiontext

EspeRare is a Geneva, Switzerland-based nonprofit foundation founded in 2013 that develops therapies for rare and neglected diseases. The organization operates two primary therapeutic programs: an initiative to expand access in Europe to individualized antisense oligonucleotide (ASO) therapies for ultra-rare and nano-rare genetic diseases, conducted in partnership with the n-Lorem Foundation; and a preeclampsia therapy development project, funded by a Bill & Melinda Gates Foundation Grand Challenges grant, that involves repurposing an oral small molecule originally developed for cardiovascular indications to improve maternal and neonatal health outcomes. Technically, EspeRare's core competency is in ASO chemistry and translational infrastructure for individualized genetic medicines, and as of January 2026 the foundation has added Pacific Biosciences' long-read whole-genome sequencing capability to its development pipeline to accelerate target validation and ASO design.

EspeRare's business model is that of a charitable foundation rather than a commercial biotech. Revenue mechanics center on foundation grants and philanthropic funding, with the Gates Foundation grant representing a major disclosed funding source. The foundation does not appear to charge patients for treatments and does not publicly disclose pricing. Its go-to-market motion is community-led and partnership-driven: EspeRare works with patient advocacy groups, clinical institutions, and strategic partners (notably n-Lorem Foundation and PacBio) to address regulatory, operational, and diagnostic barriers limiting patient access to personalized genetic medicines. Distribution occurs through clinical partnerships with healthcare institutions, initially in Switzerland as proof-of-concept, with planned expansion across the European Union.

The foundation is small (1-10 employees) and serves two distinct end-patient populations: ultra-rare and nano-rare genetic disease patients who lack access to personalized ASO therapies outside the United States, and preeclampsia patients globally. Its customer base of beneficiaries is naturally fragmented, but its operational sustainability is highly dependent on a concentrated set of strategic partners and funders. The organization is actively operating as of early 2026, evidenced by three major partnership and grant announcements within a six-week window.

Short descriptiontext

EspeRare is a Geneva-based nonprofit foundation that develops individualized antisense oligonucleotide therapies for ultra-rare genetic diseases and a repurposed small-molecule therapy for preeclampsia, serving rare disease patients and mothers globally through philanthropic grants and clinical partnerships.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersGenève, Switzerland
HQ citystring
Genève
HQ countrystring
Switzerland
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
rare disease therapeutics, antisense oligonucleotide therapy, drug repurposing, preeclampsia treatment, nonprofit biotech foundation
Industry2 codes
PRIMARYHLAAADAC
Antisense Oligonucleotides (ASO) Therapeutics (splice modulation/knockdown)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAIAIAN
Rare Pediatric & Congenital Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
NAICS code3 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
  • Voluntary Health Organizations813212
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Services-Misc Health & Allied Services, Nec8090
Product category
Rare Disease Therapeutics
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Foundation Grants and Philanthropic Funding
TypeLicensing Royalties
Description

EspeRare operates as a nonprofit foundation receiving grants and philanthropic funding to support drug development programs. The Gates Foundation Grand Challenges grant for preeclampsia research represents a major funding source.

startupticker.ch
Marketing channels1 record

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components3 values
Personnel, Technology or R&D, Operations
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

EspeRare is a Geneva-based nonprofit biotech foundation that develops therapies for rare and neglected diseases through two primary programs: individualized antisense oligonucleotide (ASO) therapies for ultra-rare genetic diseases (in partnership with the n-Lorem Foundation, expanding access from the US to Europe), and a drug-repurposing program developing an oral small molecule originally used for cardiovascular disorders to treat preeclampsia. The organization funds and coordinates translational infrastructure to deliver these treatments at no cost to patients.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • First treatments anticipated within the first year of the European collaboration
+1 more record
Product overview1 text field

EspeRare is a Geneva-based nonprofit biotech organization focused on developing novel therapies for rare genetic diseases and pregnancy complications. The organization operates two primary therapeutic programs: a preeclampsia therapy development project (funded by a Gates Foundation Grand Challenges grant) involving drug repurposing of a cardiovascular small molecule, and a European expansion initiative for individualized antisense oligonucleotide (ASO) therapies for ultra-rare genetic diseases conducted in partnership with n-Lorem Foundation. These programs aim to address unmet medical needs in rare genetic diseases and maternal health through translational infrastructure and patient access initiatives.

Product and service2 records
1Individualized ASO Therapies for Ultra-Rare Genetic Diseases
Categorytherapeutic_program
Description

Personalized antisense oligonucleotide (ASO) therapies developed and delivered to individual patients with ultra-rare and nano-rare genetic diseases through clinical partnerships, primarily serving patients in Switzerland and the EU who currently lack access to such treatments outside the United States.

2Preeclampsia Novel Therapy Development Program
Categorytherapeutic_program
Description

A drug-repurposing therapeutic program developing an oral small molecule (originally used for cardiovascular disorders) as a treatment for preeclampsia, a pregnancy complication affecting millions of women and newborns globally. The program is funded by the Gates Foundation and targets improved maternal and neonatal health outcomes.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-01-13
Description

Multi-year strategic collaboration to expand access in Europe to n-Lorem's individualized antisense oligonucleotide (ASO) therapies for patients with ultra-rare genetic diseases. The partnership addresses regulatory, operational, and diagnostic barriers limiting access to personalized genetic medicines outside the United States. Initial focus is on treating patients in Switzerland as a proof-of-concept, with subsequent expansion planned across the European Union.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-01-12
Description

Strategic collaboration to leverage PacBio's long-read whole-genome sequencing technology for developing individualized ASO therapies for ultra-rare genetic diseases. PacBio will donate sequencing reagents and provide scientific expertise for long-read genome analysis. The collaboration aims to integrate long-read WGS earlier in therapeutic development to reduce sequential testing, accelerate target validation, and improve ASO design confidence.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

The pioneering commercial ASO therapeutics company, responsible for the chemistry and many of the approved ASO drugs that underlie the individualized-ASO concept. Comparable as the dominant incumbent in antisense oligonucleotide technology that EspeRare's programs ultimately depend on.

TypeBroad incumbent
Description

Commercial leader in RNA-targeted therapies for rare genetic diseases, including PMO-based ASO drugs. Relevant as a comparator on rare-disease regulatory strategy, pricing, and infrastructure for genetic-medicine delivery.

3Fondation Maladies Rares
TypeRegional player
Description

French nonprofit foundation supporting rare-disease research and patient access in Europe. Comparable as a regional rare-disease foundation that EspeRare could partner with or be benchmarked against when expanding its EU footprint.

TypeEmerging player
Description

Clinical-stage developer of stereopure oligonucleotide therapeutics for rare genetic diseases. Comparable as a technology-forward ASO platform pursuing similar indications and patient populations.

TypeDirect peer
Description

Nonprofit developing individualized antisense and gene-based therapeutics for ultra-rare neuromuscular diseases. Shares EspeRare's mission of building patient-by-patient genetic medicines through a foundation-led model rather than a traditional commercial pathway.

TypeDirect peer
Description

Clinical-stage biotech developing RNA-editing and antisense oligonucleotide therapies for rare genetic disorders. Comparable as a focused rare-disease ASO developer whose pipeline and target patient populations overlap with EspeRare's ultra-rare mandate.

TypeDirect peer
Description

US-based nonprofit that pioneered the individualized ASO model for nano-rare patients. It is EspeRare's core strategic partner but also the closest analog in mission, technology, and patient access model — the two are effectively the US and European counterparts of the same individualized-ASO delivery system.

TypeBroad incumbent
Description

Commercial rare-disease biotech with a portfolio spanning biologics, ASO, and gene therapy. Comparable in its focus on ultra-rare and rare genetic diseases and its experience building global access infrastructure for low-prevalence therapies.

TypeOthers
Description

Nonprofit R&D organization developing treatments for neglected patients using repurposing and partnership-driven models. Comparable as a foundation-led drug developer with an analogous operating playbook to EspeRare's preeclampsia repurposing program.

TypeOthers
Description

European umbrella organization representing rare-disease patient advocacy groups. Comparable as a key ecosystem stakeholder whose policy and patient-advocacy network EspeRare's EU access strategy will depend on.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

EspeRare

Rare Disease Therapeuticsesperare.org

EspeRare is a Geneva-based nonprofit foundation that develops individualized antisense oligonucleotide therapies for ultra-rare genetic diseases and a repurposed small-molecule therapy for preeclampsia, serving rare disease patients and mothers globally through philanthropic grants and clinical partnerships.

What EspeRare does

EspeRare is a Geneva, Switzerland-based nonprofit foundation founded in 2013 that develops therapies for rare and neglected diseases. The organization operates two primary therapeutic programs: an initiative to expand access in Europe to individualized antisense oligonucleotide (ASO) therapies for ultra-rare and nano-rare genetic diseases, conducted in partnership with the n-Lorem Foundation; and a preeclampsia therapy development project, funded by a Bill & Melinda Gates Foundation Grand Challenges grant, that involves repurposing an oral small molecule originally developed for cardiovascular indications to improve maternal and neonatal health outcomes. Technically, EspeRare's core competency is in ASO chemistry and translational infrastructure for individualized genetic medicines, and as of January 2026 the foundation has added Pacific Biosciences' long-read whole-genome sequencing capability to its development pipeline to accelerate target validation and ASO design.

EspeRare's business model is that of a charitable foundation rather than a commercial biotech. Revenue mechanics center on foundation grants and philanthropic funding, with the Gates Foundation grant representing a major disclosed funding source. The foundation does not appear to charge patients for treatments and does not publicly disclose pricing. Its go-to-market motion is community-led and partnership-driven: EspeRare works with patient advocacy groups, clinical institutions, and strategic partners (notably n-Lorem Foundation and PacBio) to address regulatory, operational, and diagnostic barriers limiting patient access to personalized genetic medicines. Distribution occurs through clinical partnerships with healthcare institutions, initially in Switzerland as proof-of-concept, with planned expansion across the European Union.

The foundation is small (1-10 employees) and serves two distinct end-patient populations: ultra-rare and nano-rare genetic disease patients who lack access to personalized ASO therapies outside the United States, and preeclampsia patients globally. Its customer base of beneficiaries is naturally fragmented, but its operational sustainability is highly dependent on a concentrated set of strategic partners and funders. The organization is actively operating as of early 2026, evidenced by three major partnership and grant announcements within a six-week window.

EspeRare firmographics

Firmographics
Name
EspeRare
Website
https://esperare.org
Company type
Private
Founded year
2013
Operating status
Operating
Headcount range
11–50 employees
Short description
EspeRare is a Geneva-based nonprofit foundation that develops individualized antisense oligonucleotide therapies for ultra-rare genetic diseases and a repurposed small-molecule therapy for preeclampsia, serving rare disease patients and mothers globally through philanthropic grants and clinical partnerships.
Ownership category
akta.pro rank

EspeRare industry classification

Industry
Product category
Rare Disease Therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Voluntary Health Organizations (813212)
SIC
Biological Products, (No Disgnostic Substances) (2836), Services-Misc Health & Allied Services, Nec (8090)
akta.pro industry
PRIMARYHLAAADAC
Antisense Oligonucleotides (ASO) Therapeutics (splice modulation/knockdown)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAIAIAN
Rare Pediatric & Congenital Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals

Keywords

  • Rare disease therapeutics
  • Antisense oligonucleotide therapy
  • Drug repurposing
  • Preeclampsia treatment
  • Nonprofit biotech foundation

Where EspeRare is headquartered

Location

Headquarters

HQ city
Genève
HQ country
Switzerland
HQ region
Europe

Offices1 record

Markets served

EspeRare business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations

Revenue model

  1. Foundation Grants and Philanthropic Funding: EspeRare operates as a nonprofit foundation receiving grants and philanthropic funding to support drug development programs. The Gates Foundation Grand Challenges grant for preeclampsia research represents a major funding source.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

EspeRare product offering

Product offering

Core offering

EspeRare is a Geneva-based nonprofit biotech foundation that develops therapies for rare and neglected diseases through two primary programs: individualized antisense oligonucleotide (ASO) therapies for ultra-rare genetic diseases (in partnership with the n-Lorem Foundation, expanding access from the US to Europe), and a drug-repurposing program developing an oral small molecule originally used for cardiovascular disorders to treat preeclampsia. The organization funds and coordinates translational infrastructure to deliver these treatments at no cost to patients.

Product overview

EspeRare is a Geneva-based nonprofit biotech organization focused on developing novel therapies for rare genetic diseases and pregnancy complications. The organization operates two primary therapeutic programs: a preeclampsia therapy development project (funded by a Gates Foundation Grand Challenges grant) involving drug repurposing of a cardiovascular small molecule, and a European expansion initiative for individualized antisense oligonucleotide (ASO) therapies for ultra-rare genetic diseases conducted in partnership with n-Lorem Foundation. These programs aim to address unmet medical needs in rare genetic diseases and maternal health through translational infrastructure and patient access initiatives.

Differentiator

Problem solved

Functional benefit

Products and services

  • Individualized ASO Therapies for Ultra-Rare Genetic Diseases Personalized antisense oligonucleotide (ASO) therapies developed and delivered to individual patients with ultra-rare and nano-rare genetic diseases through clinical partnerships, primarily serving patients in Switzerland and the EU who currently lack access to such treatments outside the United States.
  • Preeclampsia Novel Therapy Development Program A drug-repurposing therapeutic program developing an oral small molecule (originally used for cardiovascular disorders) as a treatment for preeclampsia, a pregnancy complication affecting millions of women and newborns globally. The program is funded by the Gates Foundation and targets improved maternal and neonatal health outcomes.

Quantifiable outcome

  • First treatments anticipated within the first year of the European collaboration
  • +1 more outcomes

Companies that use EspeRare

Customer profile

Segments2 records

Ideal customer profiles2 records

EspeRare technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

EspeRare partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • n-Lorem FoundationcoreStrategic or Co-development Partner · 13 January 2026Multi-year strategic collaboration to expand access in Europe to n-Lorem's individualized antisense oligonucleotide (ASO) therapies for patients with ultra-rare genetic diseases. The partnership addresses regulatory, operational, and diagnostic barriers limiting access to personalized genetic medicines outside the United States. Initial focus is on treating patients in Switzerland as a proof-of-concept, with subsequent expansion planned across the European Union.
  • Pacific Biosciences (PacBio)coreStrategic or Co-development Partner · 12 January 2026Strategic collaboration to leverage PacBio's long-read whole-genome sequencing technology for developing individualized ASO therapies for ultra-rare genetic diseases. PacBio will donate sequencing reagents and provide scientific expertise for long-read genome analysis. The collaboration aims to integrate long-read WGS earlier in therapeutic development to reduce sequential testing, accelerate target validation, and improve ASO design confidence.

Scale indicators2 records

Recent moves5 records

Expansion highlights4 records

EspeRare competitors and assessment

Company assessment

Broad incumbents

  • Ionis Pharmaceuticals: The pioneering commercial ASO therapeutics company, responsible for the chemistry and many of the approved ASO drugs that underlie the individualized-ASO concept. Comparable as the dominant incumbent in antisense oligonucleotide technology that EspeRare's programs ultimately depend on.
  • Sarepta Therapeutics: Commercial leader in RNA-targeted therapies for rare genetic diseases, including PMO-based ASO drugs. Relevant as a comparator on rare-disease regulatory strategy, pricing, and infrastructure for genetic-medicine delivery.
  • Ultragenyx Pharmaceutical: Commercial rare-disease biotech with a portfolio spanning biologics, ASO, and gene therapy. Comparable in its focus on ultra-rare and rare genetic diseases and its experience building global access infrastructure for low-prevalence therapies.

Regional players

  • Fondation Maladies Rares: French nonprofit foundation supporting rare-disease research and patient access in Europe. Comparable as a regional rare-disease foundation that EspeRare could partner with or be benchmarked against when expanding its EU footprint.

Emerging players

  • Wave Life Sciences: Clinical-stage developer of stereopure oligonucleotide therapeutics for rare genetic diseases. Comparable as a technology-forward ASO platform pursuing similar indications and patient populations.

Direct peers

  • Cure Rare Disease: Nonprofit developing individualized antisense and gene-based therapeutics for ultra-rare neuromuscular diseases. Shares EspeRare's mission of building patient-by-patient genetic medicines through a foundation-led model rather than a traditional commercial pathway.
  • ProQR Therapeutics: Clinical-stage biotech developing RNA-editing and antisense oligonucleotide therapies for rare genetic disorders. Comparable as a focused rare-disease ASO developer whose pipeline and target patient populations overlap with EspeRare's ultra-rare mandate.
  • n-Lorem Foundation: US-based nonprofit that pioneered the individualized ASO model for nano-rare patients. It is EspeRare's core strategic partner but also the closest analog in mission, technology, and patient access model — the two are effectively the US and European counterparts of the same individualized-ASO delivery system.

Others

  • DNDi (Drugs for Neglected Diseases initiative): Nonprofit R&D organization developing treatments for neglected patients using repurposing and partnership-driven models. Comparable as a foundation-led drug developer with an analogous operating playbook to EspeRare's preeclampsia repurposing program.
  • EURORDIS – Rare Diseases Europe: European umbrella organization representing rare-disease patient advocacy groups. Comparable as a key ecosystem stakeholder whose policy and patient-advocacy network EspeRare's EU access strategy will depend on.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

EspeRare social profiles

Digital presence

EspeRare financial estimates

Financial estimate

Revenue estimate

Valuation estimate

EspeRare leadership team

Management profile

Number of profiles

EspeRare funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

EspeRare M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about EspeRare

What does EspeRare do?

EspeRare is a Geneva-based nonprofit biotech foundation that develops therapies for rare and neglected diseases through two primary programs: individualized antisense oligonucleotide (ASO) therapies for ultra-rare genetic diseases (in partnership with the n-Lorem Foundation, expanding access from the US to Europe), and a drug-repurposing program developing an oral small molecule originally used for cardiovascular disorders to treat preeclampsia. The organization funds and coordinates translational infrastructure to deliver these treatments at no cost to patients.

Is EspeRare a public or private company?

EspeRare is a private company. It is classified as nonprofit foundation owned and is currently operating.

When was EspeRare founded?

EspeRare was founded in 2013. It employs 11 to 50 people.

Where is EspeRare based?

EspeRare is headquartered in Genève, Switzerland, in the Europe region.

How does EspeRare make money?

One revenue line is on record: foundation Grants and Philanthropic Funding.

Who are EspeRare's main competitors?

Broad incumbents on record are Ionis Pharmaceuticals, Sarepta Therapeutics and Ultragenyx Pharmaceutical. Fondation Maladies Rares is listed as a regional player. Wave Life Sciences is listed as an emerging player. Direct peers are Cure Rare Disease, ProQR Therapeutics and n-Lorem Foundation. Others are DNDi (Drugs for Neglected Diseases initiative) and EURORDIS – Rare Diseases Europe.

Does EspeRare have an API?

No public API is recorded for EspeRare.

What industry is EspeRare in?

EspeRare's product category is Rare Disease Therapeutics. Its primary akta.pro industry code is HLAAADAC, Antisense Oligonucleotides (ASO) Therapeutics (splice modulation/knockdown), with a secondary code of HLAIAIAN, Rare Pediatric & Congenital Disorder Therapies. Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR Newswiren-Lorem and EspeRare announce European collaboration to expand access to individualized ASO Therapies for Rare Genetic DiseasesThe n-Lorem Foundation and EspeRare Foundation announced a strategic collaboration to expand access in Europe to n-Lorem's individualized antisense oligonucleotide (ASO) therapies for patients with ultra-rare genetic diseases. The partnership will initially focus on treating a small number of patients in Switzerland, with the goal of establishing a scalable model to support subsequent expansion across the European Union. The multi-year collaboration aims to address regulatory, operational, and diagnostic barriers that currently limit access to personalized genetic medicines outside the United States, with the first treatments anticipated within the first year.PR Newswiren-Lorem and EspeRare annoncent une collaboration européenne pour élargir l'accès aux thérapies ASO individualisées pour les maladies génétiques raresThe n-Lorem Foundation and EspeRare Foundation announced a strategic collaboration to expand access to individualized antisense oligonucleotide (ASO) therapies in Europe for patients with rare genetic diseases. The partnership will initially focus on treating nano-rare patients in Switzerland, with plans to develop a replicable model for broader EU expansion by overcoming regulatory, clinical, and diagnostic barriers. The multi-year collaboration includes a joint steering committee to coordinate regulatory strategy, clinical engagement, and program implementation.PR Newswiren-Lorem and EspeRare announce European collaboration to expand access to individualized ASO Therapies for Rare Genetic DiseasesThe n-Lorem Foundation and the EspeRare Foundation announced a strategic collaboration to expand access in Europe to n-Lorem's antisense oligonucleotide (ASO) therapies for patients with rare genetic diseases. The partnership aims to address regulatory, operational, and diagnostic barriers that limit access to personalized genetic medicines outside the United States. The collaboration will initially focus on treating patients in Switzerland, with the goal of establishing a scalable model for subsequent expansion across the European Union.Quiver QuantitativePacBio Announces Proposed Collaboration with n-Lorem Foundation and EspeRare to Advance Antisense Oligonucleotide Therapies for Rare Genetic DiseasesPacBio announced plans to pursue a strategic collaboration with the n-Lorem Foundation and EspeRare to leverage its long-read whole-genome sequencing technology for developing individualized antisense oligonucleotide (ASO) therapies for ultra-rare genetic diseases. Under the proposed collaboration, PacBio would provide scientific expertise and donate sequencing reagents to support target validation and molecular characterization of ASO therapies. The proposed collaboration remains subject to negotiation, introducing uncertainty regarding whether the partnership will ultimately materialize.GlobeNewswirePacBio Announces Plans for Collaboration With n-Lorem Foundation and EspeRare to Advance Precision Therapies for Rare Genetic DiseasesPacBio announced plans to pursue a strategic collaboration with the n-Lorem Foundation and EspeRare to advance precision therapies for ultra-rare genetic diseases using its long-read whole-genome sequencing technology. Under the proposed collaboration, PacBio will donate sequencing reagents and provide scientific expertise to support the development of individualized antisense oligonucleotide therapies, with the goal of establishing HiFi long-read sequencing as the preferred platform for rare disease therapeutic development. The collaboration aims to integrate genomic sequencing earlier in the therapeutic development process to accelerate target validation and improve ASO design confidence.PR NewswireEspeRare receives a grant from the Gates Foundation to advance a novel therapy for preeclampsiaEspeRare, a Geneva-based nonprofit biotech, announced it has received a Grand Challenges grant from the Gates Foundation to advance a novel therapy for preeclampsia. The funding will support the clinical evaluation of repurposing an oral small molecule originally developed for cardiovascular disorders to treat this severe pregnancy complication. This initiative aims to improve survival and health outcomes for mothers and unborn children in under-resourced settings.startupticker.chEspeRare receives a grant from the Gates Foundation to fight preeclampsiaEspeRare, a Geneva-based nonprofit biotech, has received a Grand Challenges grant from the Gates Foundation to advance development of a novel therapy for preeclampsia, a severe pregnancy complication. The grant supports repurposing an oral small molecule originally developed for cardiovascular disorders as a treatment for preeclampsia, which affects millions of women and babies annually and is a leading cause of maternal and neonatal mortality in low-resource regions. Current treatment options are limited, often leaving premature delivery as the only intervention, making this research effort aimed at creating a safe, effective, and globally accessible therapy.PR NewswireDie Laboratoires Pierre Fabre engagieren sich mit innovativen Therapien im Kampf gegen seltene Krankheiten bei KindernLaboratoires Pierre Fabre has reaffirmed its commitment to developing innovative treatments for rare diseases in children on the occasion of Rare Disease Day 2024, highlighting partnerships in three key areas: an in-utero therapy for XLHED with foundation EspeRare, an EMA-approved T-cell immunotherapy (Tabelecleucel) for PTLD EBV+ with Atara Biotherapeutics, and a treatment for infantile hemangioma developed with University Hospital Bordeaux. The company, known for its oncology and dermatology work, emphasizes that rare diseases affect over 200 million children worldwide and has also partnered with patient organizations like Ichthyose France to collect data on patient experiences.PR NewswirePierre Fabre Laboratories and the EspeRare Foundation to be honored with the EURORDIS Company Award for Patient Engagement 2024, in their approach to co-developing a treatment for XLHED.Pierre Fabre Laboratories and the EspeRare Foundation will receive the EURORDIS Company Award for Patient Engagement 2024 on February 20, 2024, in Brussels, recognizing their collaboration on developing a potential prenatal therapy for X-linked hypohidrotic ectodermal dysplasia (XLHED). The award specifically honors their patient-centered approach, having engaged the Ectodermal Dysplasia patient community as equal partners throughout the clinical development process in the ongoing EDELIFE study. The recognition highlights their work with affected families since 2018 to advance what could become the first prenatal treatment for this rare genetic disease.PR NewswirePierre Fabre and the EspeRare Foundation administer investigational treatment to first patient in EDELIFE clinical trial for rare genetic disease, XLHEDThe EspeRare Foundation and Pierre Fabre announced that the first patient has received treatment in the EDELIFE Phase II clinical trial for XLHED (X-linked Hypohidrotic Ectodermal Dysplasia), a rare genetic disease affecting approximately 4/100,000 live male births annually. The trial is groundbreaking as it represents the first-of-its-kind prenatal treatment administered to the affected baby while still in the mother's womb. The confirmatory study will enroll 15 to 20 baby boys across 8 clinical centers in Europe and the USA, with the main phase expected to continue until 2025 and long-term follow-up extending up to 5 years of age.